MX2022015279A - Diagnostico, prevencion y tratamiento de la infeccion por coronavirus. - Google Patents

Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.

Info

Publication number
MX2022015279A
MX2022015279A MX2022015279A MX2022015279A MX2022015279A MX 2022015279 A MX2022015279 A MX 2022015279A MX 2022015279 A MX2022015279 A MX 2022015279A MX 2022015279 A MX2022015279 A MX 2022015279A MX 2022015279 A MX2022015279 A MX 2022015279A
Authority
MX
Mexico
Prior art keywords
diagnosis
prevention
treatment
coronavirus infection
coronavirus
Prior art date
Application number
MX2022015279A
Other languages
English (en)
Inventor
Thomas Rademacher
Richard Perrins
Laurens Rademacher
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of MX2022015279A publication Critical patent/MX2022015279A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)

Abstract

La invención se refiere a péptidos de coronavirus, y al uso de dichos péptidos para el diagnóstico, el tratamiento y la prevención de la infección por coronavirus.
MX2022015279A 2020-06-02 2021-06-02 Diagnostico, prevencion y tratamiento de la infeccion por coronavirus. MX2022015279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2008250.9A GB202008250D0 (en) 2020-06-02 2020-06-02 Diagnosis, prevention and treatment of coronavirus infection
PCT/EP2021/064803 WO2021245140A2 (en) 2020-06-02 2021-06-02 Diagnosis, prevention and treatment of coronavirus infection

Publications (1)

Publication Number Publication Date
MX2022015279A true MX2022015279A (es) 2023-03-01

Family

ID=71526360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015279A MX2022015279A (es) 2020-06-02 2021-06-02 Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.

Country Status (13)

Country Link
US (1) US20230203103A1 (es)
EP (1) EP4157346A2 (es)
JP (1) JP2023528427A (es)
KR (1) KR20230019163A (es)
CN (1) CN115697399A (es)
AU (1) AU2021286179A1 (es)
BR (1) BR112022024594A2 (es)
CA (1) CA3180589A1 (es)
CO (1) CO2022017283A2 (es)
GB (1) GB202008250D0 (es)
IL (1) IL298717A (es)
MX (1) MX2022015279A (es)
WO (1) WO2021245140A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
CA2582668C (en) 2004-10-01 2013-10-01 Midatech Ltd Nanoparticles comprising antigens and adjuvants, and immunogenic structures
CA2617869C (en) 2005-08-04 2017-02-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
WO2007122388A2 (en) 2006-04-13 2007-11-01 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
AU2012306243B2 (en) 2011-09-07 2016-10-20 Midatech Limited Nanoparticle-peptide compositions
EA201991377A1 (ru) * 2017-01-03 2020-01-21 Эмерджекс Ваксинс Холдинг Лимитед Композиции универсальной вакцины против гриппа
US20210299241A1 (en) * 2018-05-18 2021-09-30 Emergex Vaccines Holding Limited Reverse peptide vaccine

Also Published As

Publication number Publication date
AU2021286179A1 (en) 2023-01-19
CO2022017283A2 (es) 2023-02-16
KR20230019163A (ko) 2023-02-07
WO2021245140A3 (en) 2022-02-24
US20230203103A1 (en) 2023-06-29
GB202008250D0 (en) 2020-07-15
IL298717A (en) 2023-02-01
CA3180589A1 (en) 2021-12-09
JP2023528427A (ja) 2023-07-04
CN115697399A (zh) 2023-02-03
WO2021245140A2 (en) 2021-12-09
BR112022024594A2 (pt) 2022-12-27
EP4157346A2 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
MX2022001004A (es) Inhibidores de enzimas.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
MX2022000811A (es) Inhibidores de enzimas.
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
JOP20200183A1 (ar) جزيء ربط له نشاط تحييد ضد متلازمة الشرق الأوسط التنفسية – فيروس كورونا
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2022015279A (es) Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.
WO2023122260A3 (en) Inhibitors of sars-cov-2
MX2023009041A (es) Uso de inhibidores del proteasoma en el tratamiento de infecciones por coronavirus.
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
MX2022003816A (es) Compuestos antibacterianos.
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
IL280340B (en) Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections
MX2022006342A (es) Terapia combinada de cicloserina y litio para el tratamiento de la depresion.